Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Provided By GlobeNewswire
Last update: Mar 19, 2025
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is subject to customary post-closing adjustments.
Read more at globenewswire.com
